DALLAS, March 14, 2005 (PRIMEZONE) -- Beacon Equity Research announces it has issued a new research note on Biophan Technologies, Inc. (OTCBB:BIPH) in response to the Company's latest announcement regarding the development of an MRI-compatible Vena Cava Filter. This report is authored by Senior Analyst, Shailesh Dhuri.
In the report Mr. Dhuri writes, "The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The total market for MRI safe biomedical devices and implants is estimated to be $12 billion, while the market for safe drug delivery products is estimated to be $40 billion. Biophan has amassed an impressive portfolio of 108 patents; which include 32 issued, eight allowed and 68 applications in process in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, biothermal batteries, and photonics."
He later continues, "Vena cava filters are metallic, umbrella-shaped devices that catch blood clots to prevent them from traveling to the lungs and causing a pulmonary embolism. Every year, approximately 600,000 people across the globe experience a pulmonary embolism, resulting in an estimated 60,000 to 100,000 deaths. In the U.S., approximately 250,000 hospitalizations can be traced to PE; and around 50,000 deaths can be attributed to PE."
To view this report in its entirety, please visit: http://BeaconEquityResearch.com
Registration is free.
Beacon Equity Research, LLC is a fee-based, comprehensive investment research firm, focusing primarily on the underserved small-cap sector. All Beacon analysts are seasoned industry professionals and adhere to the CFA Institute's (CFAI) stringent ethics and standards of practice guidelines. All research reports are authored by a Certified Financial Analyst (CFA), one of the most prestigious professional designations awarded in the financial industry. Beacon Research does not have any investment banking relationships with any of the companies covered, thereby eliminating a common conflict of interest between the research analyst and the company being covered. All analysts are compensated prior to performing their investment research and are not compensated in any way based on the future performance of the equities they follow. Beacon Equity Research has been compensated eighteen thousand dollars by Biophan Technologies for one year of enrollment in its research program. All opinions and conclusions are solely those of the analyst who prepared the report. The authoring analyst utilizes a host of publicly available information, which Beacon can make no representations to regarding the accuracy of. No information contained in this report should be construed as either a solicitation to buy or sell any securities listed or mentioned. Beacon Equity Research is not a registered broker/dealer. Investors are encouraged to visit http://BeaconEquityResearch.com, or email us at info@BeaconEquityResearch.com for more information regarding our company policies.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 108 U.S. patents, licenses, or applications. This total includes 32 issued U.S. patents, eight recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks and uncertainties that could cause actual results to be materially different from those projected. Such risks may include, but are not necessarily limited to, changes in general economic conditions and other business considerations described more specifically in Biophan's Securities and Exchange Commission filings.